The compound you described, **1,3-dimethyl-8-(3-methyl-1-piperidinyl)-7-[2-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]ethyl]purine-2,6-dione**, is a complex organic molecule with a long and descriptive chemical name. It's more commonly referred to by its code name, **BMS-214662**.
**BMS-214662 is a potent and selective antagonist of the adenosine A2A receptor.** Let's break down what that means:
* **Adenosine A2A Receptor:** This is a type of G protein-coupled receptor (GPCR) found in the brain and other tissues. It plays a role in various functions, including:
* **Neurotransmission:** Modulating the release of neurotransmitters like dopamine.
* **Inflammation:** Regulating inflammatory responses.
* **Cardiovascular health:** Affecting heart rate and blood pressure.
* **Antagonist:** This means BMS-214662 blocks the action of adenosine at the A2A receptor. It prevents adenosine from binding and activating the receptor.
**Why is BMS-214662 important for research?**
* **Potential Therapeutic Applications:** The ability of BMS-214662 to block the adenosine A2A receptor makes it a promising candidate for treating various conditions:
* **Parkinson's Disease:** Blocking A2A receptors can enhance dopamine signaling, potentially improving motor function.
* **Addiction:** A2A receptor antagonists show potential for reducing drug craving and withdrawal symptoms.
* **Inflammation:** Blocking A2A receptors can suppress inflammatory responses, potentially benefitting conditions like arthritis.
* **Cancer:** Some research suggests A2A receptor antagonists may have anti-tumor effects.
* **Understanding the Role of Adenosine:** Studying the effects of BMS-214662 helps researchers understand the complex roles of the adenosine A2A receptor in the body. This knowledge can be crucial for developing more targeted and effective treatments for various diseases.
**Important Note:** BMS-214662 is still in the research phase. While promising, it's important to note that it hasn't yet been approved for clinical use. More research is needed to determine its safety and efficacy for specific medical conditions.
ID Source | ID |
---|---|
PubMed CID | 5049897 |
CHEMBL ID | 1459382 |
CHEBI ID | 112187 |
Synonym |
---|
UPCMLD0ENAT5732439:001 |
MLS000101173 , |
smr000015955 |
CHEBI:112187 |
STK849890 |
1,3-dimethyl-8-(3-methylpiperidin-1-yl)-7-{2-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]ethyl}-3,7-dihydro-1h-purine-2,6-dione |
AB00434747-05 |
AKOS001294746 |
1,3-dimethyl-8-(3-methylpiperidin-1-yl)-7-[2-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]ethyl]purine-2,6-dione |
HMS2243O23 |
1,3-dimethyl-7-(2-((5-methyl-1,3,4-thiadiazol-2-yl)thio)ethyl)-8-(3-methylpiperidin-1-yl)-1h-purine-2,6(3h,7h)-dione |
850914-56-6 |
F0570-0327 |
AKOS016336795 |
CHEMBL1459382 |
Q27192289 |
1,3-dimethyl-8-(3-methyl-1-piperidinyl)-7-[2-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]ethyl]purine-2,6-dione |
Z223837890 |
Class | Description |
---|---|
oxopurine | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 0.6310 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 0.1995 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 22.3872 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 5.6607 | 0.3162 | 12.4435 | 31.6228 | AID902; AID924 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 3.1623 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
Integrin beta-3 | Homo sapiens (human) | Potency | 5.0119 | 0.3162 | 11.4157 | 31.6228 | AID924 |
Integrin alpha-IIb | Homo sapiens (human) | Potency | 5.0119 | 0.3162 | 11.4157 | 31.6228 | AID924 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 1.4125 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |